CO-LEAD for Improved Communication and Medication Adherence in Lupus
This study is testing an intervention called CO-LEAD to help people with systemic lupus erythematosus (SLE) better manage their medication. CO-LEAD aims to improve how doctors and patients talk about medication and any challenges in taking it. The study will train doctors to use effective communication strategies, review your pharmacy refill information, and work with you to find solutions for any medication adherence problems. The goal is to see if these improved discussions lead to better medication use over time. You may be able to join if you are between 18 and 90 years old and have SLE. The study is currently unclear about its recruitment status.
- Study design
- This is an interventional study with a planned enrollment of 480 participants. The study does not specify if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The frequency of adherence discussions will be measured during the intervention period, which can last up to 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Intervention to Improve Communication and Medication Adherence in Lupus
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kai Sun, MD · PRINCIPAL_INVESTIGATOR · Duke University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Frequency of adherence discussionsDuring intervention period (up to 2 years)
Proportion of SLE patient visits in which a nonjudgmental, patient-centered adherence discussion took place as determined by analysis of clinic visit audio recordings